2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.

MLA

Rodríguez-Carrio, Javier, et al. “2022 EULAR Points to Consider for the Measurement, Reporting and Application of IFN-I Pathway Activation Assays in Clinical Research and Practice.” Annals of the Rheumatic Diseases, vol. 82, no. 6, June 2023, pp. 754–62. EBSCOhost, https://doi.org/10.1136/ard-2022-223628.

APA

Rodríguez-Carrio, J., Burska, A., Conaghan, P. G., Dik, W. A., Biesen, R., Eloranta, M.-L., Cavalli, G., Visser, M., Boumpas, D. T., Bertsias, G., Wahren-Herlenius, M., Rehwinkel, J., Frémond, M.-L., Crow, M. K., Rönnblom, L., Versnel, M. A., & Vital, E. M. (2023). 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice. Annals of the Rheumatic Diseases, 82(6), 754–762. https://doi.org/10.1136/ard-2022-223628

Chicago

Rodríguez-Carrio, Javier, Agata Burska, Philip G Conaghan, Willem A Dik, Robert Biesen, Maija-Leena Eloranta, Giulio Cavalli, et al. 2023. “2022 EULAR Points to Consider for the Measurement, Reporting and Application of IFN-I Pathway Activation Assays in Clinical Research and Practice.” Annals of the Rheumatic Diseases 82 (6): 754–62. doi:10.1136/ard-2022-223628.